# Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective

> Research article (Cost Effectiveness and Resource Allocation, 2018) · cited 13× · AI/ML

**Wikidata**: [openalex:W2900568195](https://www.wikidata.org/wiki/openalex:W2900568195)  
**Source**: https://4ort.xyz/entity/cost-effectiveness-analysis-of-secukinumab-versus-other-biologics-and-apremilast-in-the-treatment-of-active-psoriatic-ar